ArticleCell reports2020
Metabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 257 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
257citing papers in PubMed, 1 pooled it
16.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
257 citing papers in PubMed, 1 synthesis or guideline pooled it, 386 citations in OpenAlex.
- Engineering the maturation of stem cell-derived cardiomyocytes.Frontiers in bioengineering and biotechnology · 2023Pooled it
- Clinical trials in a dish: cardiometabolic drug development with biological and digital twins.The Journal of clinical investigation · 2026Review
- Modeling ventricular tachycardia in genetic long QT syndrome using engineered cardiac tissues.Bioactive materials · 2026Article
- Do Stimulants Promote Arrhythmic Risk: Insights From a Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model.Journal of arrhythmia · 2026Article
- Human cardiovascular organoids: Biomedical applications and ethical challenges.American heart journal plus : cardiology research and practice · 2026Review
- Structural and functional benchmarking of monolayer- and bioreactor-generated hiPSC-derived cardiomyocytes.APL bioengineering · 2026Article
- Spatially guided in vivo single-cell functional genomics of postnatal heart.Nature cardiovascular research · 2026Article
- PRDM16 modulates aspects of cell cycle dynamics and maturation in human iPSC-derived cardiomyocytes.Stem cell reports · 2026Article
- Metabolic fatty acid substrates enhance the structural and mechanical performance of human-induced pluripotent stem cell-derived cardiomyocytes.Cellular and molecular life sciences : CMLS · 2026Article
- Oxygen-generating Microparticles Enhance Viability and Functionality of Human Pluripotent Stem Cell-derived Cardiomyocytes for Myocardial Infarction Therapy.Stem cell reviews and reports · 2026Article
- Machine learning-guided risk stratification for long QT syndrome genetic variants with hiPSC-derived cardiomyocytes.Cardiovascular research · 2026Article
- Protocol for insulin dosing during expansion and maturation of human iPSC-derived cardiomyocytes.STAR protocols · 2026Article
- Review
- Integrative circulatory engineering for regenerative therapy: Dynamic perfusion design and metabolic maturation in cardiac tissue engineering.Regenerative therapy · 2026Article
- Mitochondria Clearance Enables Macrophage-Driven Maturation of iPSC-Derived Cardiomyocyte Metabolism.Cellular and molecular bioengineering · 2026Article
- Cardiac-Derived ECM Microspheres for Enhanced hiPSC-CMs Maturation.Advanced functional materials · 2026Article
- Advanced in vitro cardiac models for drug evaluation: integration of organoids, engineered tissues, and microphysiological systems.Microsystems & nanoengineering · 2026Review
- Human plasma-like medium enhances structural and metabolic maturation of human pluripotent stem cell-derived cardiomyocytes.Bioengineering & translational medicine · 2026Article
- Modeling early human heart development using an iPSC-based 3D bioprinted model of embryonic heart tube.Nature communications · 2026Article
- Phospholipid Transfer Protein (PLTP) in Cholesterol Handling: Implications for Mitochondrial Lipid Homeostasis in Human iPSC-Derived Cardiomyocytes.International journal of molecular sciences · 2026Review
197 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 6 institutions in 3 countries.
Dries A M FeyenCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA; Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Wesley L McKeithanCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA; Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, USA; Department of Bioengineering, University of California, San Diego, San Diego, CA, USA.
Arne A N BruyneelCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Sean SpieringSanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, USA; Department of Bioengineering, University of California, San Diego, San Diego, CA, USA.
Larissa HörmannInstitute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Bärbel UlmerInstitute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hui ZhangDepartment of Bioengineering, University of California, San Diego, San Diego, CA, USA.
Francesca BrigantiCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Michaela SchweizerElectron Microscopy Unit, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Bence HegyiDepartment of Pharmacology, University of California, Davis, Davis, CA, USA.
Zhandi LiaoDepartment of Pharmacology, University of California, Davis, Davis, CA, USA.
Risto-Pekka PölönenDepartment of Pharmacology, University of California, Davis, Davis, CA, USA.
Kenneth S GinsburgDepartment of Pharmacology, University of California, Davis, Davis, CA, USA.
Chi Keung LamCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Ricardo SerranoCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Christine WahlquistCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA; Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, USA; Department of Bioengineering, University of California, San Diego, San Diego, CA, USA.
Alexander KreymermanCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Michelle VuCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Prashila L AmatyaCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Charlotta S BehrensInstitute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sara RanjbarvaziriCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Renee G C MaasCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA; Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Matthew GreenhawCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Daniel BernsteinCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Joseph C WuCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Donald M BersDepartment of Pharmacology, University of California, Davis, Davis, CA, USA.
Thomas EschenhagenInstitute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christian M MetalloDepartment of Bioengineering, University of California, San Diego, San Diego, CA, USA.
Mark MercolaCardiovascular Institute and Department of Medicine, Stanford University, Stanford, CA 94305, USA; Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, USA; Department of Bioengineering, University of California, San Diego, San Diego, CA, USA. Electronic address: mmercola@stanford.edu.
Cardiovascular Institute of the South · USUniversität Hamburg · DEUniversity of California, Davis · USSanford Burnham Prebys Medical Discovery Institute · USUniversity of California San Diego · USUtrecht University · NL
Funding
Project 3 (Mercola)P01HL141084 · NHLBI · STANFORD UNIVERSITY · PI Joseph C. Wu · 2019 to 2026
$21.1MHuman Induced Pluripotent Stem Cells for Cardiovascular Disease ModelingR01HL113006 · NHLBI · STANFORD UNIVERSITY · PI WU, JOSEPH C. · 2012 to 2025
$6.8MMicroRNA Control of Dilated CardiomyopathyR01HL130840 · NHLBI · STANFORD UNIVERSITY · PI MARK MERCOLA, Shankar Subramaniam · 2016 to 2026
$4.6MHigh-Throughput Screens to Discover Novel Inhibitors of Leaky RyR2 for Heart Failure TherapyR01HL138539 · NHLBI · UNIVERSITY OF MINNESOTA · PI BERS, DONALD M, CORNEA, RAZVAN LIVIU · 2018 to 2021
$3.1MRole of miR25 in Heart FailureR01HL128072 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAJJAR, ROGER J., MERCOLA, MARK · 2015 to 2018
$2.5MmicroRNAs and Integrative Control on Cardiopoiesis - CHANGE OF GRANTEE INSTITUTIOR01HL113601 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MERCOLA, MARK · 2012 to 2016
$2.2MSmall Molecule NOTCH Inhibitors for the treatment of pulmonary hypertensionR01HL132225 · NHLBI · STANFORD UNIVERSITY · PI MERCOLA, MARK, THISTLETHWAITE, PATRICIA A · 2016 to 2019
$1.7MOptical Pacing Using Graphene-Cardiomyocyte Interfaces for Precision Medicine and Drug DiscoveryR21HL141019 · NHLBI · STANFORD UNIVERSITY · PI MERCOLA, MARK · 2018 to 2019
$420kNHLBI NIH HHS P01 HL141084NHLBI NIH HHS R01 HL113006NHLBI NIH HHS R01 HL113601NHLBI NIH HHS R01 HL128072NHLBI NIH HHS R01 HL130840NHLBI NIH HHS R01 HL132225NHLBI NIH HHS R01 HL138539NHLBI NIH HHS R21 HL141019
Abstract
Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) have enormous potential for the study of human cardiac disorders. However, their physiological immaturity severely limits their utility as a model system and their adoption for drug discovery. Here, we describe maturation media designed to provide oxidative substrates adapted to the metabolic needs of human iPSC (hiPSC)-CMs. Compared with conventionally cultured hiPSC-CMs, metabolically matured hiPSC-CMs contract with greater force and show an increased reliance on cardiac sodium (Na
Indexed as
CalciumCardiac Conduction System DiseaseCardiomyopathy, DilatedCulture MediaGene Expression RegulationHeartHumansInduced Pluripotent Stem CellsLong QT SyndromeMembrane PotentialsModels, BiologicalMyocardial ContractionMyocytes, CardiacPhenotypeTissue EngineeringCalciumCulture Mediacardiomyocytedilated cardiomyopathydisease modelingengineered heart tissuesinduced pluripotent stem cellslong QT syndrome 3maturationphysiology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.